FARXIGA in Cardiology

FARXIGA helps save lives in patients by reducing CV death and hospitalization for heart failure.1

FARXIGA is now recommended as a component of first-line therapy according to the 2021 ACC Expert Consensus Decision Pathway.2,*,†

Start FARXIGA today in your newly diagnosed patients with HFrEF who are on an ACEI/ARB.

*2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction.

SGLT2i is recommended as first-line therapy; FARXIGA is the only SGLT2i FDA approved for use in patients with HFrEF with and without T2D as discussed in the 2021 ACC Expert Consensus Decision Pathway.2

Mortality due to heart failure is on the rise in the US3

In the US, we’ve seen a 38% increase in deaths between 2011 and 2017* in which heart failure was the underlying cause.3,† That’s one reason to remember that every patient with HFrEF remains at substantial risk and can deteriorate suddenly.4 Also consider that over 95% of patients hospitalized with HFrEF died or were readmitted within 5 years,5,‡ while approximately 1 in 8 ambulatory patients with HFrEF died without any signs of worsening heart failure within 3 years.6,§

Total number of deaths due to heart failure in the US: 2011 and 2017*

Deaths Due to Heart Failure in the USDeaths Due to Heart Failure in the US

Every patient with HFrEF remains at substantial risk and can deteriorate suddenly4

Every Patient with HFrEFEvery Patient with HFrEF

Is there more that can be done today to help protect your newly diagnosed patients with HFrEF from CV death?

*2017 US population data derived from the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research data set.3

Underlying cause of death defined as the disease or injury that initiated the series of events leading directly to death.3

In an analysis of the Get With the Guidelines-Heart Failure registry including 18,299 patients with HFrEF.5

§Among 964 patients with Stage C HFrEF in Emory Healthcare.6


ACC=American College of Cardiology; ACEI=angiotensin-converting enzyme inhibitor; ARB=angiotensin II receptor blocker; CKD=chronic kidney disease; CV=cardiovascular; FDA=US Food and Drug Administration; HFrEF=heart failure with reduced ejection fraction; SGLT2i=sodium-glucose cotransporter 2 inhibitor; T2D=type 2 diabetes.

IMPORTANT SAFETY INFORMATION FOR FARXIGA